Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | IV antiviral for COVID-19. | COVID-19 antiviral pills for people at high risk. |
| Body system | Antivirals | Antivirals |
| Drug class | RNA polymerase inhibitors | Viral protease inhibitors |
| Supply | Prescription only | Prescription only |
| Main uses | COVID-19 in hospital, Early COVID-19 in high-risk outpatients (3 days) | Mild to moderate COVID-19 in people at high risk of severe disease |
| How it works | Slips into the virus's genetic material as it's copied and stops the process. | Blocks the enzyme the coronavirus uses to cut its proteins into working parts. |
| Starts working | — | — |
| Half-life | About 1 hour (parent); metabolites longer | About 6 hours |
| Typical adult dose | 200 mg on day 1, then 100 mg daily. | 300 mg nirmatrelvir + 100 mg ritonavir twice a day for 5 days, started within 5 days of symptoms (lower dose in moderate kidney disease). |
| Forms | IV infusion | Co-packaged tablets |
| Common side effects | Nausea, Raised liver enzymes | Altered taste ('Paxlovid mouth'), Diarrhoea, Nausea |
| Serious side effects | Infusion reactions, Slow heart rate, Liver injury | Dangerous interactions with other medicines, Allergic reactions |
| Don't take if | — | — |
| Alcohol | — | — |
| Pregnancy | Use with cautionUsed when benefits outweigh risks. | Use with cautionCan be used if benefits outweigh risks; limited data. |
| Breastfeeding | — | — |
| In use since | 2020 | 2021 |
| Brand names | United States: VekluryUnited Kingdom: VekluryIndia: Covifor, Cipremi | United States: PaxlovidUnited Kingdom: PaxlovidAustralia: Paxlovid |
| Legal status | — | — |
| ATC code | J05AB16 | — |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker